Skip to main content
Top

Open Access 14-10-2024 | Bacterial Peritonitis | Original Article

Long-term safety profile of sutimlimab in adult Japanese patients with cold agglutinin disease

Authors: Yoshitaka Miyakawa, Eriko Sato, Yoshiaki Ogawa, Jun-ichi Nishimura, Masashi Nishimi, Osamu Kawaguchi, Sayaka Tahara, Masaki Yamaguchi

Published in: International Journal of Hematology

Login to get access

Abstract

Sutimlimab, a complement inhibitor, has recently been approved in Japan for treating cold agglutinin disease (CAD). We report the safety and efficacy of sutimlimab in Japanese patients with CAD who completed a global phase 3 clinical trial (CARDINAL/CADENZA: 26-week treatment with 1–2 years of open-label extension [OLE] periods) and subsequently participated in the Japanese OLE study. Patients with a recent history of blood transfusion (CARDINAL, n = 3) and those without (CADENZA, n = 4) were analyzed (71.4% female; median [range] baseline age: 70 [46–83] years). For CARDINAL/CADENZA, the treatment duration (median [range]) was 140.9 (104.9–157.3) weeks, and the cessation period was 70 (61–133) weeks. For the Japanese OLE study, the treatment duration was 47.1 (15.1–49.1) weeks. Three (42.9%) patients experienced treatment-related and treatment-emergent adverse events (TEAEs): injection site erythema, cystitis bacterial, viral infection, and blood pressure increased during CARDINAL/CADENZA. One (14.3%) patient experienced one treatment-related TEAE (urinary tract infection) during the Japanese OLE study. One patient died of renal failure, considered unrelated to sutimlimab, that was exacerbated by hepatorenal syndrome due to liver cirrhosis and bacterial peritonitis, in addition to CKD. Hemoglobin and bilirubin levels improved during treatment but deteriorated after withdrawal and recovered on retreatment. Sutimlimab was well tolerated over a median of 3.8 years, with no new safety concerns identified during retreatment.
Appendix
Available only for authorised users
Literature
4.
go back to reference Berentsen S, Ulvestad E, Langholm R, et al. Primary chronic cold agglutinin disease: a population based clinical study of 86 patients. Haematologica. 2006;91:460–6.PubMed Berentsen S, Ulvestad E, Langholm R, et al. Primary chronic cold agglutinin disease: a population based clinical study of 86 patients. Haematologica. 2006;91:460–6.PubMed
13.
go back to reference Röth A, Broome CM, Barcellini W, et al. Sutimlimab provides clinically meaningful improvements in patient-reported outcomes in patients with cold agglutinin disease: Results from the randomised, placebo-controlled, Phase 3 CADENZA study. Eur J Haematol. 2023;110:280–8. https://doi.org/10.1111/ejh.13903.CrossRefPubMed Röth A, Broome CM, Barcellini W, et al. Sutimlimab provides clinically meaningful improvements in patient-reported outcomes in patients with cold agglutinin disease: Results from the randomised, placebo-controlled, Phase 3 CADENZA study. Eur J Haematol. 2023;110:280–8. https://​doi.​org/​10.​1111/​ejh.​13903.CrossRefPubMed
Metadata
Title
Long-term safety profile of sutimlimab in adult Japanese patients with cold agglutinin disease
Authors
Yoshitaka Miyakawa
Eriko Sato
Yoshiaki Ogawa
Jun-ichi Nishimura
Masashi Nishimi
Osamu Kawaguchi
Sayaka Tahara
Masaki Yamaguchi
Publication date
14-10-2024
Publisher
Springer Nature Singapore
Published in
International Journal of Hematology
Print ISSN: 0925-5710
Electronic ISSN: 1865-3774
DOI
https://doi.org/10.1007/s12185-024-03842-9
SPONSORED

Recent advances in the use of CAR T-cell therapies in relapsed/refractory diffuse large B-cell lymphoma and follicular lymphoma

  • Webinar | 01-10-2024 | 12:30 (CEST)

In this webinar, Professor Martin Dreyling and an esteemed international panel of CAR T-cell therapy experts discuss the latest data on the safety, efficacy, and clinical impact of CAR T-cell therapies in the treatment of r/r DLBCL and r/r FL.

Please note, this webinar is not intended for healthcare professionals based in the US and UK.

Sponsored by:
  • Novartis Pharma AG
Chaired by: Prof. Martin Dreyling
Developed by: Springer Healthcare
Get a reminder for the on-demand version